% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Michaelides:303012,
      author       = {S. Michaelides and V. Hartmann and V. Nüssler and C.
                      Zielinski and M. von Bergwelt-Baildon$^*$ and S. Kobold$^*$},
      title        = {11th {I}mmunotherapy of {C}ancer conference ({ITOC}): {A}
                      meeting report.},
      journal      = {Human vaccines $\&$ immunotherapeutics},
      volume       = {21},
      number       = {1},
      issn         = {2164-5515},
      address      = {Austin, Tex.},
      publisher    = {Landes Bioscience},
      reportid     = {DKFZ-2025-01459},
      pages        = {2532967},
      year         = {2025},
      abstract     = {The Immunotherapy of Cancer (ITOC) meeting is an
                      international conference providing a platform for
                      immuno-oncologists worldwide to present and discuss their
                      research and newest findings. Being held in Munich annually,
                      the 11th edition took place in April 2025 and saw broad
                      discussions about new concepts in the field of
                      immuno-oncology, mixed with exciting clinical results but
                      also with a glimpse back into the past. This was mirrored by
                      the lifetime achievement award, given to Robert D. Schreiber
                      for his groundbreaking work on the immune surveillance of
                      cancer. ITOC11 impressively showcase how far immuno-oncology
                      has come in a conference extending from the discipline's
                      very beginnings up to some of the most exciting new findings
                      in the field of cancer immunology. The conference has
                      demonstrated that tumor immunology is not only about cancer
                      and immune cells, but extends far beyond.},
      keywords     = {Humans / Neoplasms: therapy / Neoplasms: immunology /
                      Immunotherapy: methods / Congresses as Topic / Cancer
                      Vaccines: immunology / CAR T cell therapy (Other) / ITOC
                      (Other) / Immunotherapy of Cancer (Other) / antibody therapy
                      (Other) / cellular therapy (Other) / combination therapy
                      (Other) / tumor immunology (Other) / tumor vaccination
                      (Other) / Cancer Vaccines (NLM Chemicals)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40679247},
      doi          = {10.1080/21645515.2025.2532967},
      url          = {https://inrepo02.dkfz.de/record/303012},
}